Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ari M. Vander Walde"'
Autor:
Jonathan W. Friedberg, Ann S. LaCasce, Peter Martin, Anthony J. Dodds, Mitchell R. Smith, Michael Bar, Ari M. Vander Walde, Tricia Ellis, Saurabh Rajguru, Jordan A. Herst, Kristen N. Ganjoo, Richard van der Jagt, Zhengming Chen, Michael E. Williams, Paul G. Montgomery, Bryn Pressnail, Katherine Sue Robinson, Nancy L. Bartlett, Bruce D. Cheson, Fernando Cabanillas, Bernard Lemieux, Robin Joyce, Jeff Szer, John P. Leonard
Publikováno v:
Blood. 126:3961-3961
Background Given the widespread use of bendamustine, data on long-term outcomes are essential for patients and clinicians to understand potential risks and benefits of therapy. Despite a long history as treatment for indolent non-Hodgkin lymphoma (iN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::203eb06ed977e5f05df72721680078dc
https://doi.org/10.1182/blood.v126.23.3961.3961
https://doi.org/10.1182/blood.v126.23.3961.3961
Autor:
Auayporn Nademanee, Can-Lan Sun, Liton Francisco, Stephen J. Forman, Smita Bhatia, Anthony S. Stein, Neal Kogut, Saro H. Armenian, Ari M. Vander Walde, Amrita Krishnan, Jennifer Berano Teh, F. Lennie Wong, Leslie Popplewell
Publikováno v:
Blood. 116:933-933
Abstract 933 Background: aHCT is offered with curative intent to patients with hematologic malignancies. However, survival estimates are conventionally computed from time of transplantation. These estimates provide initial prognosis, but do not refle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fa1b52c09ab93d3f8504dd3e4effdd9
https://doi.org/10.1182/blood.v116.21.933.933
https://doi.org/10.1182/blood.v116.21.933.933